Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia
- PMID: 26340131
- DOI: 10.1016/j.ijcard.2015.08.146
Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia
Abstract
Background: Familial hypercholesterolemia (FH) is characterized by elevated LDL-cholesterol and increased risk of premature coronary artery disease (CAD). Lipoprotein(a) [Lp(a)] increases CAD in FH, although the independence of this association relative to other CAD risk factors remains unclear. In this study, we examined the association between Lp(a) and other cardiovascular risk factors and prevalent CAD in patients with FH.
Methods: A cross-sectional study of 390 patients with genetically confirmed FH were studied. Clinical and biochemical parameters of FH patients with and without CAD were compared.
Results: FH patients with CAD were older and more often male and had a higher prevalence of hypertension, smoking, diabetes, obesity, reduced eGFR, and elevated plasma Lp(a) and pre-treatment LDL-cholesterol and triglyceride (or low HDL-cholesterol) than FH patients without CAD (P<0.05 for all). In univariate analyses, age, male gender, smoking, hypertension, reduced eGFR, diabetes, obesity, plasma creatinine, Lp(a) and pretreatment LDL-cholesterol, triglycerides and HDL-cholesterol levels were significant predictors of CAD in the FH patients (P<0.05 for all). Elevated LDL-cholesterol, raised Lp(a), hypertension and reduced eGFR remained significant independent predictors of CAD (P<0.05 for all) in FH after adjusting for other modifiable risk factors.
Conclusions: Elevated Lp(a), hypertension and renal insufficiency are independent risk factors beyond elevated pretreatment LDL-cholesterol which predict CAD in patients with FH. In spite of the cross-sectional design of our study, we propose the need for identifying and managing these abnormalities to reduce excess CAD risk in FH patients. However, this proposal remains to be formally tested in a prospective study.
Keywords: Cardiovascular disease; Familial hypercholesterolemia; Risk factors.
Copyright © 2015. Published by Elsevier Ireland Ltd.
Similar articles
-
Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.Atherosclerosis. 2017 May;260:67-74. doi: 10.1016/j.atherosclerosis.2017.03.021. Epub 2017 Mar 18. Atherosclerosis. 2017. PMID: 28351002
-
Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.Clin Cardiol. 2018 Mar;41(3):378-384. doi: 10.1002/clc.22880. Epub 2018 Feb 26. Clin Cardiol. 2018. PMID: 29480541 Free PMC article.
-
Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia.J Atheroscler Thromb. 2025 Jan 1;32(1):100-110. doi: 10.5551/jat.65009. Epub 2024 Aug 6. J Atheroscler Thromb. 2025. PMID: 39111867 Free PMC article.
-
The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.Dan Med Bull. 2002 Nov;49(4):318-45. Dan Med Bull. 2002. PMID: 12553167 Review.
-
Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.Atherosclerosis. 2019 Feb;281:25-30. doi: 10.1016/j.atherosclerosis.2018.11.040. Epub 2018 Dec 7. Atherosclerosis. 2019. PMID: 30616181 Review.
Cited by
-
Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN.medRxiv [Preprint]. 2023 Nov 15:2023.11.14.23298547. doi: 10.1101/2023.11.14.23298547. medRxiv. 2023. Update in: Atherosclerosis. 2024 May;392:117525. doi: 10.1016/j.atherosclerosis.2024.117525. PMID: 38014132 Free PMC article. Updated. Preprint.
-
Lipoprotein metabolism in familial hypercholesterolemia.J Lipid Res. 2021;62:100062. doi: 10.1016/j.jlr.2021.100062. Epub 2021 Mar 3. J Lipid Res. 2021. PMID: 33675717 Free PMC article. Review.
-
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.Circ Cardiovasc Genet. 2016 Jun;9(3):240-9. doi: 10.1161/CIRCGENETICS.116.001381. Epub 2016 Mar 24. Circ Cardiovasc Genet. 2016. PMID: 27013694 Free PMC article.
-
The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia.Curr Atheroscler Rep. 2020 Sep 1;22(11):64. doi: 10.1007/s11883-020-00884-2. Curr Atheroscler Rep. 2020. PMID: 32870376 Free PMC article. Review.
-
Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017.J Atheroscler Thromb. 2018 Aug 1;25(8):751-770. doi: 10.5551/jat.CR003. Epub 2018 Jun 7. J Atheroscler Thromb. 2018. PMID: 29877295 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous